↓ Skip to main content

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors

Overview of attention for article published in Investigational New Drugs, June 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

patent
2 patents

Citations

dimensions_citation
64 Dimensions

Readers on

mendeley
56 Mendeley
Title
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
Published in
Investigational New Drugs, June 2012
DOI 10.1007/s10637-012-9825-7
Pubmed ID
Authors

Gary K. Schwartz, Richard D. Carvajal, Rachel Midgley, Scott J. Rodig, Paul K. Stockman, Ozlem Ataman, David Wilson, Shampa Das, Geoffrey I. Shapiro

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 56 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 20%
Researcher 10 18%
Student > Bachelor 6 11%
Student > Master 5 9%
Student > Postgraduate 4 7%
Other 8 14%
Unknown 12 21%
Readers by discipline Count As %
Agricultural and Biological Sciences 13 23%
Biochemistry, Genetics and Molecular Biology 11 20%
Medicine and Dentistry 8 14%
Chemistry 2 4%
Nursing and Health Professions 1 2%
Other 7 13%
Unknown 14 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2017.
All research outputs
#7,541,526
of 23,007,887 outputs
Outputs from Investigational New Drugs
#327
of 1,175 outputs
Outputs of similar age
#55,208
of 165,941 outputs
Outputs of similar age from Investigational New Drugs
#4
of 17 outputs
Altmetric has tracked 23,007,887 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,175 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 165,941 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.